Executive Summary
The global biomanufacturing industry is undergoing a major transformation fueled by a surge in biologics demand, the rise of advanced therapeutic modalities, and a growing emphasis on resilient, regional manufacturing ecosystems. This strategic analysis focuses on three key dimensions:
Merger & Acquisition (M&A) Activities
Global Capacity Expansion
Regional Manufacturing Dynamics
This insight-rich report serves as a forward-looking guide for CDMOs, biopharma innovators, and investors aiming to understand the evolving competitive landscape and prepare for growth opportunities.
M&A Activities: Driving Platform Expansion & Technological Leverage
Between 2020 and 2024, M&A activity within the biomanufacturing sector has accelerated as key players seek proprietary technologies, end-to-end service capabilities, and global expansion. Notable acquisitions reflect strategic intent to integrate viral vector production, plasmid DNA, sterile fill-finish, and modular biologics infrastructure to better support both traditional biologics and emerging modalities like cell and gene therapy.
Highlighted Strategic Deals:
Novo Holdings (2024) – Acquired Catalent for $16.5B, expanding deeply into biologics.
Ampersand (2024) – Acquired Avid Bioservices for $1.1B to access scalable biologics infrastructure.
PCI Pharma Services (2025) – Acquired Ajinomoto Althea to boost North America-based sterile fill-finish.
Zydus (2025) – Secured U.S.-based biologics manufacturing plants for $125M.
AstraZeneca (2025) – Acquired EsoBiotec for up to $1B to expand into oncology-focused CDMO services.
These deals exemplify how companies are using acquisitions to gain scale, speed, and diversified platforms essential for next-gen therapies.
Capacity Expansion: Biomanufacturing on a Global Growth Trajectory
Biomanufacturing infrastructure is scaling rapidly across Asia-Pacific, North America, and Europe. Key trends include adoption of:
Single-use bioreactor systems
Continuous manufacturing platforms
Multi-modality capabilities (mRNA, microbial, mammalian, cell/gene therapy)
These investments prioritize speed-to-market, redundancy, and regulatory flexibility.
Highlighted Expansion Projects:
Samsung Biologics (Plant 5, South Korea): Adds 180kL capacity; en route to becoming world’s largest CDMO site.
WuXi Biologics (China & U.S.): Dual-chamber lyophilization and 15,000L microbial capacity expansion in Chengdu; 24kL commercial-scale site in Massachusetts.
Fujifilm Diosynth: Major projects in the U.S. (Holly Springs, Thousand Oaks), UK (Billingham) with modular and microbial expansions.
These infrastructure developments position CDMOs to support broader therapeutic pipelines and meet global biologics demand.
Regional Biomanufacturing Footprint Analysis (2024–2025)
The biomanufacturing landscape is decentralizing, with regional hubs gaining strategic significance based on cost, policy, infrastructure, and local biotech ecosystems.
- North America
Innovation-driven capacity expansion (e.g., Fujifilm Diosynth, Resilience)
Strong federal support for gene/cell therapy and mRNA production
- Europe
Germany, Ireland, UK emerging as injectable biologics hubs
Vetter Pharma, Thermo Fisher expanding sterile injectables and microbial capabilities
- Asia-Pacific
South Korea, China, India investing heavily in CDMO capacity
Cost advantages and supportive government policies boosting CDMO appeal
- Latin America & MEA
Brazil, Mexico scaling vaccine fill-finish and packaging infrastructure
Regional growth fueled by public-private partnerships and WHO-aligned standards
Global Trends & Strategic Outlook
North America remains the global leader in innovation-led biologics manufacturing
Asia-Pacific is the fastest-growing market with emphasis on cell/gene therapy and mRNA platforms
Regional manufacturing is replacing centralized models to boost resilience and reduce time-to-market
Conclusion
The global biomanufacturing sector is evolving rapidly in response to complex demand drivers, including advanced biologics pipelines, pandemic preparedness, and geopolitical shifts. Companies that embrace modular, tech-forward capacity and leverage strategic M&A will be best positioned to lead in this new era.
At SCSEAPWIMCELV | 360 Business & Marketing Solution, we deliver in-depth industry insights and strategic advisory to help biopharma brands, CDMOs, and investors navigate these transformative shifts and unlock long-term growth opportunities.